Herbert A. Schmid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Herbert A. Schmid has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
E. Scharrer
Institute of Veterinary Physiology, University of Zurich, Switzerland
1 shared publicationM. Traebert
Department of Metabolic and Cardiovascular Diseases, Obesity Biology (Basle), Novartis Pharma AG, Switzerland
1 shared publicationPhilippe Schoeffter
1 shared publicationS. Whitebread
Department of Metabolic and Cardiovascular Diseases, Obesity Biology (Basle), Novartis Pharma AG, Switzerland
1 shared publicationT. Riediger
Institute of Veterinary Physiology, University of Zurich, Switzerland
1 shared publication
Latest Publications
- 1 October 2004
- Published by S. Karger AG in Neuroendocrinology
- Vol. 80 (Suppl. 1) , 47-50
Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide and lanreotide treat patients with these tumors by binding preferentially to sst2 and, to a lesser extent, to sst3 and sst5 receptors, thereby controlling prominent symptoms caused by hormone hypersecretion (diarrhea and flushing). Although symptoms initially improve in most patients, a loss of response occurs in about 50% during continuous treatment. The functional activity at sst receptors of SOM230, a new multiligand somatostatin analog, has been described and compared with that of somatostatin (SRIF-14) and octreotide. These data show that SOM230 is a full agonist with nanomolar potency at sst1,2,3 and sst5 receptors. The multiligand activity profile of SOM230, together with its nondesensitizing inhibitory effect on growth hormone and insulin-like growth factor-I secretion in rats, may underlie its successful use in clinical trials and its potential for use in refractory patients with carcinoid tumors.
- 1 October 2004
- Published by S. Karger AG in Neuroendocrinology
- Vol. 80 (Suppl. 1) , 47-50
Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors
Functional gastroenteropancreatic tumors express all 5 somatostatin receptor subtypes (sst) in different quantities. Octreotide and lanreotide treat patients with these tumors by binding preferentially to sst2 and, to a lesser extent, to sst3 and sst5 receptors, thereby controlling prominent symptoms caused by hormone hypersecretion (diarrhea and flushing). Although symptoms initially improve in most patients, a loss of response occurs in about 50% during continuous treatment. The functional activity at sst receptors of SOM230, a new multiligand somatostatin analog, has been described and compared with that of somatostatin (SRIF-14) and octreotide. These data show that SOM230 is a full agonist with nanomolar potency at sst1,2,3 and sst5 receptors. The multiligand activity profile of SOM230, together with its nondesensitizing inhibitory effect on growth hormone and insulin-like growth factor-I secretion in rats, may underlie its successful use in clinical trials and its potential for use in refractory patients with carcinoid tumors.
- 24 June 2002
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 14 (7) , 580-586
Ghrelin Acts on Leptin‐Responsive Neurones in the Rat Arcuate Nucleus
Leptin decreases food intake and increases energy expenditure in rodents by inhibiting neurones in the hypothalamic arcuate nucleus. The growth hormone secretagogue (GHS) ghrelin is known to stimulate food intake and to be the endogenous ligand for the GHS‐receptor, which is strongly expressed in the arcuate nucleus, like the leptin receptor (Ob‐R). In this study, we analysed the effect of systemic ghrelin administration on Fos expression in the arcuate nucleus on neurones expressing Ob‐R. Injection of ghrelin (0.2 mg/kg, i.p) significantly increased the number of neurones expressing Fos protein in the ventromedial arcuate nucleus. Fifty‐seven percent of all Fos‐positive cells in the ventromedial arcuate nucleus were also positive for Ob‐R staining. Furthermore, we investigated electrophysiologically the effect of ghrelin and leptin on the activity of arcuate neurones in an in‐vitro slice preparation. Ghrelin stimulated the electrical activity dose‐dependently in 80% of all cells tested (n=49) with a threshold concentration of 10−11 M; only 8% were inhibited and 12% did not respond. The effect of ghrelin (10−7 M) was weakly antagonized by the peptidic GHS‐receptor antagonist (D‐Lys3)‐GHRP‐6 (10−4 M), which also showed a much weaker affinity (IC50, 0.9 × 10−6 M) to the GHS‐receptor than ghrelin (IC50, 0.3 × 10−9 M). Ghrelin increased the electrical activity in 76% of all cells which were inhibited by leptin (n=17). These data show that ghrelin interacts with the leptin hypothalamic network in the arcuate nucleus. The opposite effect of leptin and ghrelin on neurones in the arcuate nucleus may serve as a neurophysiological correlate of the orexigenic and anorectic effects of ghrelin and leptin.
- 24 June 2002
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 14 (7) , 580-586
Ghrelin Acts on Leptin‐Responsive Neurones in the Rat Arcuate Nucleus
Leptin decreases food intake and increases energy expenditure in rodents by inhibiting neurones in the hypothalamic arcuate nucleus. The growth hormone secretagogue (GHS) ghrelin is known to stimulate food intake and to be the endogenous ligand for the GHS‐receptor, which is strongly expressed in the arcuate nucleus, like the leptin receptor (Ob‐R). In this study, we analysed the effect of systemic ghrelin administration on Fos expression in the arcuate nucleus on neurones expressing Ob‐R. Injection of ghrelin (0.2 mg/kg, i.p) significantly increased the number of neurones expressing Fos protein in the ventromedial arcuate nucleus. Fifty‐seven percent of all Fos‐positive cells in the ventromedial arcuate nucleus were also positive for Ob‐R staining. Furthermore, we investigated electrophysiologically the effect of ghrelin and leptin on the activity of arcuate neurones in an in‐vitro slice preparation. Ghrelin stimulated the electrical activity dose‐dependently in 80% of all cells tested (n=49) with a threshold concentration of 10−11 M; only 8% were inhibited and 12% did not respond. The effect of ghrelin (10−7 M) was weakly antagonized by the peptidic GHS‐receptor antagonist (D‐Lys3)‐GHRP‐6 (10−4 M), which also showed a much weaker affinity (IC50, 0.9 × 10−6 M) to the GHS‐receptor than ghrelin (IC50, 0.3 × 10−9 M). Ghrelin increased the electrical activity in 76% of all cells which were inhibited by leptin (n=17). These data show that ghrelin interacts with the leptin hypothalamic network in the arcuate nucleus. The opposite effect of leptin and ghrelin on neurones in the arcuate nucleus may serve as a neurophysiological correlate of the orexigenic and anorectic effects of ghrelin and leptin.